Chun-Su Lee
Comptroller/Controller/Auditor bij NOVMETAPHARMA CO., LTD.
Vermogen: 222 677 $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Chun-Su Lee
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 11 | |
NovMetaHealth Co. Ltd.
NovMetaHealth Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. develops and manufactures products related to metabolic diseases. The company is based in Seoul, South Korea. The South Korean company was founded in 2016. Seon-Wook Hwang has been the CEO of the company since 2016. NovMetaHealth Co. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Chun-Su Lee via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Seoul National University | College/University | Doctorate Degree Doctorate Degree | |
Pohang University of Science & Technology | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
University of Ulsan | College/University | Corporate Officer/Principal | |
University of Massachusetts | College/University | Doctorate Degree | |
Sogang University | College/University | Graduate Degree | |
Hanyang University | College/University | Undergraduate Degree | |
Kyungpook National University | College/University | Corporate Officer/Principal | |
DONGWON F&B CO., LTD. | Food: Major Diversified | Director/Board Member | |
The Trustees of Columbia University in The City of New York | College/University | Graduate Degree | |
Mitobridge, Inc.
Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
David Geffen School of Medicine | College/University | Undergraduate Degree | |
Stritch School of Medicine | College/University | Undergraduate Degree | |
Inha University | College/University | Graduate Degree | |
PNC Holdings Co. Ltd. | Chief Executive Officer | ||
Chung-Ang University | College/University | Graduate Degree | |
École Polytechnique Fédérale de Lausanne | College/University | Corporate Officer/Principal | |
Reamol Biomedical Consulting Sàrl LLC | Chief Executive Officer | ||
Katholieke Universiteit Leuven | College/University | Doctorate Degree | |
Handong Global University | College/University | Graduate Degree |
Statistieken
Internationaal
Zuid-Korea | 12 |
Verenigde Staten | 6 |
Zwitserland | 3 |
Frankrijk | 2 |
België | 2 |
Sectoraal
Consumer Services | 16 |
Health Technology | 3 |
Consumer Non-Durables | 2 |
Operationeel
Director/Board Member | 13 |
Graduate Degree | 8 |
Undergraduate Degree | 8 |
Corporate Officer/Principal | 7 |
Doctorate Degree | 6 |
Sterkste connecties
Insiders | |
---|---|
Johan Auwerx | 6 |
Seon-Wook Hwang | 4 |
Sang-Joon Kim | 4 |
Hoi-Yoon Jung | 4 |
Mun-Jin Song | 3 |
Gi-Eop Lee | 3 |
In-Gyu Lee | 3 |
Jong-Man Seol | 3 |
Gyung-Tae Kim | 3 |
Heon-Jong Lee | 2 |
Jae-Ryong Lee | 1 |
- Beurs
- Insiders
- Chun-Su Lee
- Bedrijfsconnecties